Egg Allergy develops when immune system of the body becomes sensitized and overreacts to proteins in egg whites and/or yolks. When eggs are eaten, the body recognizes the protein as a foreign substance and sends out chemicals to provide protection against it. Those chemicals cause the symptoms of an allergic reaction. According to the experts, about 2 percent of children are allergic to eggs. Although, studies show that about 70 percent of children with an Egg Allergy will recover from the condition by age of16.
DelveInsight’s, “Egg Allergy Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Egg Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request for free sample report: https://www.delveinsight.com/sample-request/egg-allergy-pipeline-insight
Some of Egg Allergy Companies are:
- Aimmune Therapeutics
- DBV Technologies
- ASIT Biotech
- And Many Others
Request for free sample report: https://www.delveinsight.com/sample-request/egg-allergy-pipeline-insight
Current Egg Allergy Treatment Scenario and Egg Allergy Emerging Therapies:
- How many companies are developing Egg Allergy drugs?
- How many Egg Allergy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Egg Allergy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Egg Allergy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Egg Allergy and their status?
- What are the key designations that have been granted to the emerging drugs?
Some of Egg Allergy therapies are:
- AR201 Powder
- Viaskin Egg (Egg Allergy Immunotherapy)
- And Many Others
Request for free sample report: https://www.delveinsight.com/sample-request/egg-allergy-pipeline-insight
Table of Contents:
Introduction
Executive Summary
Egg Allergy: Overview
Pipeline Therapeutics
Therapeutic Assessment
Egg Allergy – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
- Egg Allergy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Egg Allergy Collaboration Deals
Late Stage Products (Phase III)
- Comparative Analysis
Drug name: Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
- Comparative Analysis
AR201: Aimmune Therapeutics
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
- Comparative Analysis
Viaskin Egg (Egg Allergy immunotherapy): DBV Technologies
Drug profiles in the detailed report…..
Inactive Products
Egg Allergy Key Companies
Egg Allergy Key Products
Egg Allergy- Unmet Needs
Egg Allergy- Market Drivers and Barriers
Egg Allergy- Future Perspectives and Conclusion
Egg Allergy Analyst Views
Egg Allergy Key Companies
Appendix
Request for Deatiled TOC: https://www.delveinsight.com/sample-request/egg-allergy-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/egg-allergy-pipeline-insight